Recent Updates
Recently added Catalysts

film containing BXCL501

Phase 1

Agitation | Small molecule | Psychiatry |BioXcel Therapeutics, Inc.|Last Updated: Aug 11, 2026

Target and mechanism

ModalitySmall molecule

Also known as Sublingual film containing BXCL501 (Dexmedetomidine)

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment135

FDA Designations

BREAKTHROUGH_THERAPYFAST_TRACK

Clinical trial landscape

film containing BXCL501 · 1 trial · 2 indications

Phase 1 1
NCT04010305Sub-Lingual Dexmedetomidine in Agitation Associated With SchizophreniaAgitation
COMPLETED135 Analytics
PHASE1COMPLETED
Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia
AgitationUnlock trial analytics

Study Endpoints

Primary Endpoints

PANSS-EC Change From Baseline
120 minutes

Positive and Negative Syndrome Scale - Excited Component (PEC). The PEC comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (minimum) to 7 (maximum). The PEC, the sum of these 5 subscales, thus ranges from 5 to 35.

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
PlaceboPLACEBO_COMPARATORSublingual Film with no active drug; single administration with the possibility of repeating dose after 1 hour in case of lack of significant efficacy
20 microgramsEXPERIMENTALSublingual Film containing 20 micrograms BXCL501; single administration with the possibility of repeating dose after 1 hour in case of lack of significant efficacy
60 microgramsEXPERIMENTALSublingual Film containing 60 micrograms BXCL501; single administration with the possibility of repeating dose after 1 hour in case of lack of significant efficacy
120 microgramsEXPERIMENTAL2 Sublingual Films, each containing 60 micrograms BXCL501; single administration of 2 films with the possibility of repeating dose after 1 hour in case of lack of significant efficacy
180 microgramsEXPERIMENTAL2 Sublingual Films, each containing 60 micrograms BXCL501.

Interventions

NameTypeDescription
Sublingual film containing BXCL501 (Dexmedetomidine)DRUGSublingual film containing BXCL501 (Dexmedetomidine) for the treatment of agitation associated with Schizophrenia
Placebo filmDRUGPlacebo film for BXCL501
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersNo
Study Sites12

Inclusion Criteria: 1. Male and female patients between the ages of 18 to 65 years, inclusive. 2. Patients who have met Diagnostic and Statistical Manual (DSM) -5 criteria for schizophrenia, schizoaffective, or schizophreniform disorder. 3. Patients who are judged to be clinically agitated at Basel...

Countries:United States
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

MEDIUMSep 11, 2026NCT04010305TRIAL_REMOVED: changed
MEDIUMSep 11, 2026NCT04010305TRIAL_REMOVED: changed
MEDIUMSep 11, 2026NCT04010305TRIAL_REMOVED: changed